DocWire News Editors

DocwireNews

A research team has recently found that a common antifungal drug may be an effective treatment for patients with cystic fibrosis. These results come from a study in which human cells and animal models of the disease were found to respond to the medication, amphotericin. When administered the drug, the lung cells began functioning in a manner that could help patients fight the chronic bacterial lung infections commonly associated with cystic fibrosis. Carried out by researchers from the University of Illinois and the University of Iowa and supported in part by the National Heart, Lung, and Blood Institute (NHLBI) part of the National Institutes of Health, this work will appear in the journal Nature.&ldquo;Instead of trying do gene therapy &ndash; which is not yet effective in the lung &ndash; or to correct the protein, our approach is different. We use a small molecule surrogate that can perform the channel function of the missing protein, which we call a molecular prosthetic,&rdquo; said Dr. Martin D. Burke, study leader, professor of chemistry at Illinois, and associate dean for research at the Carle Illinois College of Medicine.Cystic fibrosis is a disease that persists throughout one&rsquo;s life and increases susceptibility to lung infections. Treatment options exist for some patients; however, no cure has been identified. Use of amphotericin restored immune function of lung tissue in human samples as well as in pigs with cystic fibrosis. The drug worked effectively regardless of the genetic mutation causing the disease, potentially making it the first treatment that can apply to all types of cystic fibrosis.<iframe loading="lazy" src="https://www.youtube.com/embed/rVX-tNaccSI" width="560" height="315" frameborder="0" allowfullscreen="allowfullscreen"></iframe><a href="https://proddocwire.wpengine.com/docwire-pick/treatment-drug-resistant-bacteria/">READ MORE:&nbsp;New Treatment Affective Against Drug-resistant Bacteria</a>The layer of liquid coating the surface of the lungs help protect against infection, but excessive thickening of this mucus layer is often associated with the disease. Cells that line the lung secrete bicarbonate into the liquid layer to regulate pH and make it uninhabitable to infectious bacteria. Cystic fibrosis is characterized by the lack of functioning GFTR, a membrane protein needed to channel bicarbonate to the surface.<h1>New Approach to Treatment</h1>Burke&rsquo;s group has been researching the channel-forming properties of amphotericin for years. In this newest study, the group aimed to use the medication in treating cystic fibrosis. The team found that amphotericin was able to form channels on the surface of lung tissue membrane&rsquo;s donated by people with cystic fibrosis caused by mutation in the CFTR gene. These channels released bicarbonate that had been built up in cells and reduced the pH and thickness of the liquid on the lung membrane back to a normal range.Unlike medications that target the defective CFTR proteins and work to adjust the improper protein folding, the use of amphotericin bypasses the defected protein by forming new channels. Also, in the 10% of cystic fibrosis patients who lack the protein altogether, there is no option to correct CFTR structure being that it is absent. This new approach to treating cystic fibrosis is especially profound in these cases, where it may be the only option.&ldquo;Whereas many of the latest advances in cystic fibrosis treatment have been targeted to specific mutations, this approach would benefit everyone with cystic fibrosis, regardless of mutation,&rdquo; said Emily Kramer-Golinkoff, co-founder of the nonprofit cystic fibrosis research foundation Emily&rsquo;s Entourage, which partially funded the research. &ldquo;Second, and perhaps even more importantly, this approach presents an opportunity to repurpose an existing, approved drug and bring it to the clinic quickly.&rdquo;<a href="https://proddocwire.wpengine.com/docwire-pick/cystic-fibrosis-and-rare-inflammatory-diseases/">READ MORE:&nbsp;Cystic Fibrosis and Rare Inflammatory Diseases</a>Going forward, the Illinois-Iowa research team intends to conduct clinical trials to test amphotericin&rsquo;s efficacy in treating humans with cystic fibrosis.&ldquo;Since amphotericin is an already approved drug, the path to clinical translation is more direct. It&rsquo;s already been shown to be safe when delivered directly to the lung, and it doesn&rsquo;t get into the rest of the body, so we can avoid the negative side effects that the drug is known for,&rdquo; said Burke. &ldquo;We are hoping to conduct clinical trials soon, especially with people for whom correctors are not beneficial.&rdquo;&ldquo;The cystic fibrosis community is truly in need of new therapies to reduce the burden of this disease. We are interested to see how this potential treatment performs in clinical trials in the future,&rdquo; said Dr. James Kiley, director of the Division of Lung Diseases at NHLBI.<blockquote class="twitter-tweet" data-lang="en">
Exciting research from a team led by <a href="https://twitter.com/ILLINOISmed?ref_src=twsrc%5Etfw">@ILLINOISmed</a> faculty Dr. Marty Burke, published in <a href="https://twitter.com/nature?ref_src=twsrc%5Etfw">@nature</a>: An approved drug normally used to treat fungal infections has potential to become the first treatment to address all types of cystic fibrosis.<a href="https://t.co/Cx4HpWZsCv">https://t.co/Cx4HpWZsCv</a> <a href="https://twitter.com/hashtag/ILLINOIS?src=hash&amp;ref_src=twsrc%5Etfw">#ILLINOIS</a>
&mdash; University of Illinois Research Park (@UIResearchPark) <a href="https://twitter.com/UIResearchPark/status/1106176831118548992?ref_src=twsrc%5Etfw">March 14, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><a href="https://proddocwire.wpengine.com/docwire-pick/future-of-medicine-picks/fda-approves-ketamine-derived-nasal-spray-treatment-for-depression/">READ MORE:&nbsp;FDA Approves Ketamine-Derived Nasal Spray Treatment for Depression</a>Source: <a href="https://news.illinois.edu/view/6367/761728#image-1">University of Illinois</a>

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Antifungal Drug Could Function as an Effective Treatment for Cystic Fibrosis

Future of Medicine

A research team has recently found that a common antifungal drug may be an effective treatment for patients with cystic fibrosis. These results come from a study in which ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe